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BACKGROUND: Recent longitudinal studies have emphasised the prognostic
value of noninvasive tests of liver fibrosis and cross-sectional studies have shown
their combination significantly improves diagnostic accuracy.
AIM: To compare the prognostic accuracy of six blood fibrosis tests and liver
biopsy, and evaluate if test combination improves the liver-prognosis assessment in
chronic hepatitis C (CHC).
METHODS: A total of 373 patients with compensated CHC, liver biopsy (Metavir
F) and blood tests targeting fibrosis (APRI, FIB4, Fibrotest, Hepascore,
FibroMeter) or cirrhosis (CirrhoMeter) were included. Significant liver-related
events (SLRE) and liver-related deaths were recorded during follow-up (started the
day of biopsy).
RESULTS: During the median follow-up of 9.5 years (3508 person-years), 47
patients had a SLRE and 23 patients died from liver-related causes. For the
prediction of first SLRE, most blood tests allowed higher prognostication than
Metavir F [Harrell C-index: 0.811 (95% CI: 0.751-0.868)] with a significant increase
for FIB4: 0.879 [0.832-0.919] (P = 0.002), FibroMeter: 0.870 [0.812-0.922] (P =
0.005) and APRI: 0.861 [0.813-0.902] (P = 0.039). Multivariate analysis identified
FibroMeter, CirrhoMeter and sustained viral response as independent predictors of
first SLRE. CirrhoMeter was the only independent predictor of liver-related death.
The combination of FibroMeter and CirrhoMeter classifications into a new FM/CM
classification improved the liver-prognosis assessment compared to Metavir F
staging or single tests by identifying five subgroups of patients with significantly
different prognoses.
CONCLUSIONS: Some blood fibrosis tests are more accurate than liver biopsy for
determining liver prognosis in CHC. A new combination of two complementary
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